Aurobindo Pharma on Friday said its wholly owned subsidiary TheraNym Biologics Pvt Ltd (TheraNym) has entered into a master service agreement with Merck Sharpe & Dohme Singapore for contract manufacturing of biologicals.
TheraNym is an affiliate of another Aurobindo Pharma subsidiary CuraTeQ Biologics Pvt Ltd.
The master service agreement, inked effective May 31, 2024, will see TheraNym contract manufacture biologicals for the domestic and international markets.
As part of the pact, TheraNym will be investing Rs 1,000 crore in setting up a biologics manufacturing facility at Borapatla in Hathnoora mandal of Medak district in Telangana. The proposed facility will have large scale bioreactors for any mammalian cell culture product and a vial filling isolator line for commercial drug product manufacturing upto 25-30 million vials per annum.
“TheraNym will build the manufacturing facility, manufacture the products and supply to MSD as per the arrangement,” Aurobindo said in a statement.